Verena Hultsch

Company: Sanofi

Job title: Director - Global Medical Affairs Dermatology & Dupilumab Atopic Dermatitis

Seminars:

Exploration of Phase 3 Data: Superior & Significant Efficacy Challenging Approved Therapies 9:30 am

Measuring efficacy: Discover how therapeutic effects on biomarkers linked to core immuno-derm disease (eg. skin lesions, itch, sleep, and quality of life) are measured   Documenting durability of response for multiple indications through inhibition of cytokine signallingRead more

day: Day One